Barrett's Oesophagus

Dysplastic Barrett’s is associated with an increased risk of developing esophageal adenocarcinoma.^1,2

The majority of individuals with Barrett’s esophagus are undiagnosed in Europe.³

Radiofrequency Ablation has been shown to reduce neoplastic progression in patients with high grade dysplasia (HGD) and low grade dysplasia (LGD).^4,5

The new Barrx™ 360 Express RFA Balloon Catheter eliminates the need for a sizing step helping physicians lower procedural time by up to 20%¹¹ by reducing procedural steps and enhancing ease-of-use features, including the ability to custom fit the device to various esophagus diameter sizes.

Its Adjustable Custom Fit Provides Targeted Precision Therapy - Allowing Physician Ease and Efficiency.

1. Sharma P, McQuaid K, Dent J, et al. A critical review of the diagnosis and management of Barrett's esophagus: the AGA Chicago Workshop. Gastroenterology 2004;127:310–330.
2. Sharma P. Clinical practice. Barrett's esophagus. N Engl J Med 2009;361:2548–2556
3. Lao Sirieix P, Fitzgerald RC, et al. Screening for oesophageal cancer. Nat Rev Clin Oncol 9: 2012; 278-287
4. Phoa et al. Radiofrequency Ablation vs Endoscopic Surveillance for Patients With Barrett Esophagus and Low-Grade Dysplasia: A Randomized Clinical Trial. JAMA. 2014;311(12):1209-1217. doi:10.1001/jama.2014.2511
5. Shaheen et al. Radiofrequency ablation in Barrett’s esophagus with dysplasia. N Engl J Med 2009;360:2277-88.
6. Sant M, et al. EUROCARE-4. Survival of cancer patients diagnosed in 1995-1999. Results and commentary. 2009 Apr;45(6):931-91. doi: 10.1016/j.ejca.2008.11.018. Epub 2009 Jan 24.
7. Ferlay J, et al. Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur J Cancer. 2013 Apr;49(6):1374-403. doi: 10.1016/j.ejca.2012.12.027.
8. Pohl H, Welch G, et al. The role of over diagnosis and reclassification in the marked increase of esophageal adenocarcinoma incidence. J Natl Cancer Inst. 2005;97:142-6. 1133-45. doi: 10.1002/ijc.27711. Epub 2012 Jul 26.
9. Internally derived estimate based on indirect costs in lost productivity in France (€555 million) from oesophageal cancer.
10. Whiteman DC, et al. Australian clinical practice guidelines for the diagnosis and management of Barrett's esophagus and early esophageal adenocarcinoma. J Gastroenterol Hepatol 2015; 30: 804-20.
11. K. Belghazi, R. E. Pouw, C. M. Sondermeijer, Et Al. Safety And Efficacy Of Circumferential Radiofrequency Ablation Of Barrett’s Esophagus Using The Barrx™ 360 Express Rfa Balloon Catheter: Results Of A Pilot Study.

Select your country/language

Contact & Support

The Statistics

Early detection is essential to reduce the risk of progressing to Barrett’s oesophagus and/or oesophageal cancer

The Goal of Intervention is to prevent disease progression¹⁰

Barrx^TM Endoscopic RFA Therapy

Corporate Resources

Medical Surgical Portfolio

Additional Resources

Medtronic Limited

©2025 Medtronic